Base de dados : MEDLINE
Pesquisa : D12.776.124.920 [Categoria DeCS]
Referências encontradas : 1989 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 199 ir para página                         

  1 / 1989 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28715494
[Au] Autor:Ourradi K; Xu Y; de Seny D; Kirwan J; Blom A; Sharif M
[Ad] Endereço:School of Clinical Sciences, University of Bristol, Musculoskeletal Research Unit, Learning and Research Building, Southmead Hospital, Bristol, United Kingdom.
[Ti] Título:Development and validation of novel biomarker assays for osteoarthritis.
[So] Source:PLoS One;12(7):e0181334, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Osteoarthritis (OA) is the most common chronic joint disease usually diagnosed at relatively advanced stages when there is irreparable damage to the joint(s). Recently, we have identified two novel biomarkers C3f and V65 which appear to be OA-specific and therefore potential markers of early disease. We report the development of immunoassays for quantitative measure of these two novel biomarkers. METHOD: Monoclonal and polyclonal antibodies were generated by immunising mouse and rabbits respectively with peptide-carrier conjugates of C3f and V65. Affinity purified antibodies were used for immunoassays development and assays validated using serum from OA patients and controls. RESULTS: The ELISAs developed showed spiked recovery of up to 96% for C3f and V65 peptides depending on serum dilutions with a coefficient of variation (CV) <10%. The intra- and inter-assay CVs for C3f and V65 were 1.3-10.8% and 4.2-10.3% respectively. Both assays were insensitive for measurements of the peptides in patients and the use of different signal amplification systems did not increase assay sensitivity. CONCLUSION: We have developed two immunoassays for measurements of C3f and V65 peptides biomarkers discovered by our earlier proteomic study. These assays could detect the endogenous peptides in serum samples from patients and controls but lacked sensitivity for accurate measurements of the peptides in patients. Our study highlights the difficulties and challenges of validating biomarker from proteomic studies and demonstrates how to overcome some of the technical challenges associated with developing immunoassays for small peptides.
[Mh] Termos MeSH primário: Biomarcadores/sangue
Complemento C3b/análise
Ensaio de Imunoadsorção Enzimática/métodos
Osteoartrite/sangue
Fragmentos de Peptídeos/sangue
Vitronectina/sangue
[Mh] Termos MeSH secundário: Animais
Formação de Anticorpos
Western Blotting
Seres Humanos
Camundongos
Osteoartrite/diagnóstico
Osteoartrite/imunologia
Coelhos
Sensibilidade e Especificidade
[Pt] Tipo de publicação:JOURNAL ARTICLE; VALIDATION STUDIES
[Nm] Nome de substância:
0 (Biomarkers); 0 (Peptide Fragments); 0 (Vitronectin); 0 (complement C3f); 80295-43-8 (Complement C3b)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171024
[Lr] Data última revisão:
171024
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170718
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0181334


  2 / 1989 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28666984
[Au] Autor:Martí-Pàmies I; Cañes L; Alonso J; Rodríguez C; Martínez-González J
[Ad] Endereço:Instituto de Investigaciones Biomédicas de Barcelona (IIBB-CSIC), Sant Pau Biomedical Research Institute, Barcelona, Spain.
[Ti] Título:The nuclear receptor NOR-1/NR4A3 regulates the multifunctional glycoprotein vitronectin in human vascular smooth muscle cells.
[So] Source:FASEB J;31(10):4588-4599, 2017 Oct.
[Is] ISSN:1530-6860
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The nuclear receptor NOR-1 (NR4A3) has recently been involved in the regulation of extracellular matrix (ECM) proteins associated with neointimal thickening and the vascular control of hemostasis. We sought to find as-yet unidentified NOR-1 target genes in human vascular smooth muscle cells (VSMCs). An analysis identified putative NOR-1 response elements in the proximal promoter region of several genes encoding for ECM proteins, including vitronectin (VTN). Lentiviral overexpression of NOR-1 strongly increased VTN mRNA and protein levels, whereas NOR-1 silencing significantly reduced VTN expression. Deletion and site-directed mutagenesis studies, as well as EMSA and chromatin immunoprecipitation, identified the NBRE(-202/-195) site in the promoter as an essential element for NOR-1 responsiveness. Furthermore, NOR-1 and VTN colocalized in VSMCs in human atherosclerotic lesions. VTN levels were increased in cell supernatants from VSMCs that overexpress NOR-1. Cell supernatants from VSMCs overexpressing NOR-1 induced cell migration to a greater extent than supernatants from control cells, and this effect was attenuated when cell supernatants were preincubated with anti-VTN blocking antibodies or VTN was silenced in supernatant-generating cells. These results indicate that VTN is a target of NOR-1 and suggest that this multifunctional glycoprotein may participate in vascular responses mediated by this nuclear receptor.-Martí-Pàmies, I., Cañes, L., Alonso, J., Rodríguez, C., Martínez-González, J. The nuclear receptor NOR-1/NR4A3 regulates the multifunctional glycoprotein vitronectin in human vascular smooth muscle cells.
[Mh] Termos MeSH primário: Glicoproteínas/metabolismo
Proteínas de Membrana Transportadoras/metabolismo
Músculo Liso Vascular/metabolismo
Miócitos de Músculo Liso/metabolismo
Vitronectina/metabolismo
[Mh] Termos MeSH secundário: Movimento Celular/fisiologia
Células Cultivadas
Proteínas da Matriz Extracelular/metabolismo
Seres Humanos
Regiões Promotoras Genéticas/genética
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Extracellular Matrix Proteins); 0 (Glycoproteins); 0 (Membrane Transport Proteins); 0 (OSCP1 protein, human); 0 (Vitronectin)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171019
[Lr] Data última revisão:
171019
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170702
[St] Status:MEDLINE
[do] DOI:10.1096/fj.201700136RR


  3 / 1989 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28299286
[Au] Autor:Fish AI; Riley SP; Singh B; Riesbeck K; Martinez JJ
[Ad] Endereço:Vector-Borne Diseases Laboratories, Department of Pathobiological Sciences, Louisiana State University School of Veterinary Medicine Baton Rouge, LA, USA.
[Ti] Título:The Adr1 Interacts with the C-Terminus of Human Vitronectin in a Salt-Sensitive Manner.
[So] Source:Front Cell Infect Microbiol;7:61, 2017.
[Is] ISSN:2235-2988
[Cp] País de publicação:Switzerland
[La] Idioma:eng
[Ab] Resumo:Spotted fever group (SFG) species are inoculated into the mammalian bloodstream by hematophagous arthropods. Once in the bloodstream and during dissemination, the survival of these pathogens is dependent upon the ability of these bacteria to evade serum-borne host defenses until a proper cellular host is reached. expresses an outer membrane protein, Adr1, which binds the complement inhibitory protein vitronectin to promote resistance to the anti-bacterial effects of the terminal complement complex. Adr1 is predicted to consist of 8 transmembrane beta sheets that form a membrane-spanning barrel with 4 peptide loops exposed to the extracellular environment. We previously demonstrated that Adr1 derivatives containing either loop 3 or 4 are sufficient to bind Vn and mediate resistance to serum killing when expressed at the outer-membrane of . By expressing Adr1 on the surface of non-pathogenic , we demonstrate that the interaction between Adr1 and vitronectin is salt-sensitive and cannot be interrupted by addition of heparin. Additionally, we utilized vitroenctin-derived peptides to map the minimal Adr1/vitronectin interaction to the C-terminal region of vitronectin. Furthermore, we demonstrate that specific charged amino acid residues located within loops 3 and 4 of Adr1 are critical for mediating resistance to complement-mediated killing. Interestingly, Adr1 mutants that were no longer sufficient to mediate resistance to serum killing still retained the ability to bind to Vn, suggesting that Adr1-Vn interactions responsible for resistance to serum killing are more complex than originally hypothesized. In summary, elucidation of the mechanisms governing Adr1-Vn binding will be useful to specifically target this protein-protein interaction for therapeutic intervention.
[Mh] Termos MeSH primário: Proteínas da Membrana Bacteriana Externa/metabolismo
Interações Hospedeiro-Patógeno
Mapeamento de Interação de Proteínas
Rickettsia conorii/fisiologia
Sais/metabolismo
Vitronectina/metabolismo
[Mh] Termos MeSH secundário: Proteínas da Membrana Bacteriana Externa/genética
Escherichia coli/genética
Escherichia coli/metabolismo
Expressão Gênica
Seres Humanos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Bacterial Outer Membrane Proteins); 0 (Salts); 0 (Vitronectin)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:171007
[Lr] Data última revisão:
171007
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170317
[St] Status:MEDLINE
[do] DOI:10.3389/fcimb.2017.00061


  4 / 1989 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28150868
[Au] Autor:Prasada RT; Lakshmi PT; Parvathy R; Murugavel S; Karuna D; Paritosh J
[Ad] Endereço:Division of Biochemistry, Indian Veterinary Research Institute, Izatnagar 243122, Uttar Pradesh, India.
[Ti] Título:Identification of second arginine-glycine-aspartic acid motif of ovine vitronectin as the complement C9 binding site and its implication in bacterial infection.
[So] Source:Microbiol Immunol;61(2):75-84, 2017 Feb.
[Is] ISSN:1348-0421
[Cp] País de publicação:Australia
[La] Idioma:eng
[Ab] Resumo:Vitronectin (Vn), a multifunctional protein of blood and extracellular matrix, interacts with complement C9. This interaction may modulate innate immunity. Details of Vn-C9 interactions are limited. Vn-C9 interactions were assessed by employing a goat homologous system and observing Vn binding to C9 in three different assays. Using recombinant fragments, C9 binding was mapped to the N-terminus of Vn. Site directed mutagenesis was performed to alter the second arginine glycine aspartic acid (RGD) sequence (RGD-2) of Vn. Changing R to G or D to A in RGD-2 caused significant decrease in Vn binding to C9 whereas changing of R to G in the first RGD motif (RGD-1) had no effect on Vn binding to C9. These results imply that the RGD-2 of goat Vn is involved in C9 binding. In a competitive binding assay, the presence of soluble RGD peptide inhibited Vn binding to C9 whereas heparin had no effect. Vn binding to C9 was also evaluated in terms of bacterial pathogenesis. Serum dependent inhibition of Escherichia coli growth was significantly reverted when Vn or its N-fragment were included in the assay. The C-fragment, which did not support C9 binding, also partly nullified serum-dependent inhibition of bacterial growth, probably through other serum component(s).
[Mh] Termos MeSH primário: Motivos de Aminoácidos
Complemento C9/metabolismo
Fatores Imunológicos/metabolismo
Vitronectina/metabolismo
[Mh] Termos MeSH secundário: Animais
Sítios de Ligação
Atividade Bactericida do Sangue
Complemento C9/imunologia
Análise Mutacional de DNA
Escherichia coli/imunologia
Cabras
Fatores Imunológicos/imunologia
Mutagênese Sítio-Dirigida
Ligação Proteica
Vitronectina/genética
Vitronectina/imunologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Complement C9); 0 (Immunologic Factors); 0 (Vitronectin)
[Em] Mês de entrada:1704
[Cu] Atualização por classe:170418
[Lr] Data última revisão:
170418
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170203
[St] Status:MEDLINE
[do] DOI:10.1111/1348-0421.12468


  5 / 1989 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28121998
[Au] Autor:Martins CO; Demarchi L; Ferreira FM; Pomerantzeff PM; Brandao C; Sampaio RO; Spina GS; Kalil J; Cunha-Neto E; Guilherme L
[Ad] Endereço:Heart Institute (InCor), School of Medicine, University of São Paulo, São Paulo, São Paulo, Brazil.
[Ti] Título:Rheumatic Heart Disease and Myxomatous Degeneration: Differences and Similarities of Valve Damage Resulting from Autoimmune Reactions and Matrix Disorganization.
[So] Source:PLoS One;12(1):e0170191, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Autoimmune inflammatory reactions leading to rheumatic fever (RF) and rheumatic heart disease (RHD) result from untreated Streptococcus pyogenes throat infections in individuals who exhibit genetic susceptibility. Immune effector mechanisms have been described that lead to heart tissue damage culminating in mitral and aortic valve dysfunctions. In myxomatous valve degeneration (MXD), the mitral valve is also damaged due to non-inflammatory mechanisms. Both diseases are characterized by structural valve disarray and a previous proteomic analysis of them has disclosed a distinct profile of matrix/structural proteins differentially expressed. Given their relevance in organizing valve tissue, we quantitatively evaluated the expression of vimentin, collagen VI, lumican, and vitronectin as well as performed immunohistochemical analysis of their distribution in valve tissue lesions of patients in both diseases. We identified abundant expression of two isoforms of vimentin (45 kDa, 42 kDa) with reduced expression of the full-size protein (54 kDa) in RHD valves. We also found increased vitronectin expression, reduced collagen VI expression and similar lumican expression between RHD and MXD valves. Immunohistochemical analysis indicated disrupted patterns of these proteins in myxomatous degeneration valves and disorganized distribution in rheumatic heart disease valves that correlated with clinical manifestations such as valve regurgitation or stenosis. Confocal microscopy analysis revealed a diverse pattern of distribution of collagen VI and lumican into RHD and MXD valves. Altogether, these results demonstrated distinct patterns of altered valve expression and tissue distribution/organization of structural/matrix proteins that play important pathophysiological roles in both valve diseases.
[Mh] Termos MeSH primário: Doenças Autoimunes/patologia
Prolapso da Valva Mitral/patologia
Cardiopatia Reumática/patologia
[Mh] Termos MeSH secundário: Adulto
Doenças Autoimunes/imunologia
Doenças Autoimunes/metabolismo
Colágeno Tipo VI/análise
Matriz Extracelular/química
Feminino
Perfilação da Expressão Gênica
Seres Humanos
Lumicana/análise
Masculino
Meia-Idade
Valva Mitral/química
Prolapso da Valva Mitral/etiologia
Prolapso da Valva Mitral/imunologia
Prolapso da Valva Mitral/metabolismo
Domínios Proteicos
Proteômica
Cardiopatia Reumática/imunologia
Cardiopatia Reumática/metabolismo
Vimentina/análise
Vitronectina/análise
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Collagen Type VI); 0 (LUM protein, human); 0 (Lumican); 0 (Vimentin); 0 (Vitronectin)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170818
[Lr] Data última revisão:
170818
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170126
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0170191


  6 / 1989 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27989923
[Au] Autor:Varun D; Srinivasan GR; Tsai YH; Kim HJ; Cutts J; Petty F; Merkley R; Stephanopoulos N; Dolezalova D; Marsala M; Brafman DA
[Ad] Endereço:School of Biological and Health Systems Engineering, Arizona State University, United States.
[Ti] Título:A robust vitronectin-derived peptide for the scalable long-term expansion and neuronal differentiation of human pluripotent stem cell (hPSC)-derived neural progenitor cells (hNPCs).
[So] Source:Acta Biomater;48:120-130, 2017 Jan 15.
[Is] ISSN:1878-7568
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Despite therapeutic advances, neurodegenerative diseases and disorders remain some of the leading causes of mortality and morbidity in the United States. Therefore, cell-based therapies to replace lost or damaged neurons and supporting cells of the central nervous system (CNS) are of great therapeutic interest. To that end, human pluripotent stem cell (hPSC) derived neural progenitor cells (hNPCs) and their neuronal derivatives could provide the cellular 'raw material' needed for regenerative medicine therapies for a variety of CNS disorders. In addition, hNPCs derived from patient-specific hPSCs could be used to elucidate the underlying mechanisms of neurodegenerative diseases and identify potential drug candidates. However, the scientific and clinical application of hNPCs requires the development of robust, defined, and scalable substrates for their long-term expansion and neuronal differentiation. In this study, we rationally designed a vitronectin-derived peptide (VDP) that served as an adhesive growth substrate for the long-term expansion of several hNPC lines. Moreover, VDP-coated surfaces allowed for the directed neuronal differentiation of hNPC at levels similar to cells differentiated on traditional extracellular matrix protein-based substrates. Overall, the ability of VDP to support the long-term expansion and directed neuronal differentiation of hNPCs will significantly advance the future translational application of these cells in treating injuries, disorders, and diseases of the CNS.
[Mh] Termos MeSH primário: Diferenciação Celular/efeitos dos fármacos
Células-Tronco Neurais/citologia
Neurônios/citologia
Peptídeos/farmacologia
Células-Tronco Pluripotentes/citologia
Vitronectina/farmacologia
[Mh] Termos MeSH secundário: Animais
Adesão Celular/efeitos dos fármacos
Moléculas de Adesão Celular/metabolismo
Proliferação Celular/efeitos dos fármacos
Materiais Revestidos Biocompatíveis/farmacologia
Proteínas da Matriz Extracelular/metabolismo
Seres Humanos
Camundongos
Células-Tronco Neurais/efeitos dos fármacos
Células-Tronco Neurais/metabolismo
Neurônios/efeitos dos fármacos
Neurônios/metabolismo
Células-Tronco Pluripotentes/efeitos dos fármacos
Células-Tronco Pluripotentes/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Cell Adhesion Molecules); 0 (Coated Materials, Biocompatible); 0 (Extracellular Matrix Proteins); 0 (Peptides); 0 (Vitronectin)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171020
[Lr] Data última revisão:
171020
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161220
[St] Status:MEDLINE


  7 / 1989 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27808427
[Au] Autor:Hu P; Luo BH
[Ad] Endereço:Department of Biological Sciences, Louisiana State University, Baton Rouge, Louisiana.
[Ti] Título:Integrin α ß Adopts a High Affinity State for Soluble Ligands Under Physiological Conditions.
[So] Source:J Cell Biochem;118(8):2044-2052, 2017 Aug.
[Is] ISSN:1097-4644
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:It has been proposed that integrins adopt a low affinity conformation under physiological conditions. Integrin can either be activated through cytoplasm or by binding of cations such as Mn to the head domain. The cytoplasmic activation pathway, that is, inside-out signaling has been regarded as the physiological pathway for integrin activation. Integrin ß is important for neuron vascular development. However, due to the highly divergent cytoplasmic domain, this integrin probably does not rely on inside-out signaling for affinity regulation. We therefore hypothesized that the ß integrin uniquely assumes a constitutively high affinity state under physiological conditions. We discovered that ß indeed exhibited high binding to soluble vitronectin in the presence of Ca and the ligand binding could not be further enhanced by addition of Mn . The lower ectodomain stalk of the integrin, which is comprised by the integrin epidermal growth factor-like (I-EGF) domains and ßTD domain, is critical for this high affinity conformation. In addition, we found that unlike other integrins, Mg at low concentration inhibited ß ligand binding. Mutagenesis studies indicated that ß integrin possesses a unique cation binding site which might contribute to the ligand binding affinity. Our study showed that both the ß lower ectodomain stalk and the head domain play an important role in its high affinity state under physiological conditions. J. Cell. Biochem. 118: 2044-2052, 2017. © 2016 Wiley Periodicals, Inc.
[Mh] Termos MeSH primário: Cálcio/química
Integrina alfa5/química
Cadeias beta de Integrinas/química
Proteínas Recombinantes de Fusão/química
Vitronectina/química
[Mh] Termos MeSH secundário: Sequência de Aminoácidos
Sítios de Ligação
Cálcio/metabolismo
Cátions Bivalentes
Expressão Gênica
Células HEK293
Seres Humanos
Integrina alfa5/genética
Integrina alfa5/metabolismo
Cadeias beta de Integrinas/genética
Cadeias beta de Integrinas/metabolismo
Ligantes
Magnésio/química
Magnésio/metabolismo
Manganês/química
Manganês/metabolismo
Mutação
Ligação Proteica
Domínios Proteicos
Proteínas Recombinantes de Fusão/genética
Proteínas Recombinantes de Fusão/metabolismo
Alinhamento de Sequência
Homologia de Sequência de Aminoácidos
Solubilidade
Soluções
Vitronectina/genética
Vitronectina/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Cations, Divalent); 0 (Integrin alpha5); 0 (Integrin beta Chains); 0 (Ligands); 0 (Recombinant Fusion Proteins); 0 (Solutions); 0 (Vitronectin); 0 (integrin beta8); 42Z2K6ZL8P (Manganese); I38ZP9992A (Magnesium); SY7Q814VUP (Calcium)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171102
[Lr] Data última revisão:
171102
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161104
[St] Status:MEDLINE
[do] DOI:10.1002/jcb.25780


  8 / 1989 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27798934
[Au] Autor:Mühlenkamp MC; Hallström T; Autenrieth IB; Bohn E; Linke D; Rinker J; Riesbeck K; Singh B; Leo JC; Hammerschmidt S; Zipfel PF; Schütz MS
[Ad] Endereço:Institute for Medical Microbiology and Hygiene, University Hospital Tübingen, Tübingen, Germany.
[Ti] Título:Vitronectin Binds to a Specific Stretch within the Head Region of Yersinia Adhesin A and Thereby Modulates Yersinia enterocolitica Host Interaction.
[So] Source:J Innate Immun;9(1):33-51, 2017.
[Is] ISSN:1662-8128
[Cp] País de publicação:Switzerland
[La] Idioma:eng
[Ab] Resumo:Complement resistance is an important virulence trait of Yersinia enterocolitica (Ye). The predominant virulence factor expressed by Ye is Yersinia adhesin A (YadA), which enables bacterial attachment to host cells and extracellular matrix and additionally allows the acquisition of soluble serum factors. The serum glycoprotein vitronectin (Vn) acts as an inhibitory regulator of the terminal complement complex by inhibiting the lytic pore formation. Here, we show YadA-mediated direct interaction of Ye with Vn and investigated the role of this Vn binding during mouse infection in vivo. Using different Yersinia strains, we identified a short stretch in the YadA head domain of Ye O:9 E40, similar to the 'uptake region' of Y. pseudotuberculosis YPIII YadA, as crucial for efficient Vn binding. Using recombinant fragments of Vn, we found the C-terminal part of Vn, including heparin-binding domain 3, to be responsible for binding to YadA. Moreover, we found that Vn bound to the bacterial surface is still functionally active and thus inhibits C5b-9 formation. In a mouse infection model, we demonstrate that Vn reduces complement-mediated killing of Ye O:9 E40 and, thus, improved bacterial survival. Taken together, these findings show that YadA-mediated Vn binding influences Ye pathogenesis.
[Mh] Termos MeSH primário: Adesinas Bacterianas/metabolismo
Vitronectina/metabolismo
Yersiniose/imunologia
Yersinia enterocolitica/fisiologia
[Mh] Termos MeSH secundário: Animais
Bacteriólise
Proteínas do Sistema Complemento/metabolismo
Interações Hospedeiro-Patógeno
Seres Humanos
Imunidade Inata
Imunomodulação
Camundongos
Camundongos Endogâmicos C57BL
Ligação Proteica
Domínios Proteicos/genética
Especificidade da Espécie
Virulência
Vitronectina/genética
Yersinia enterocolitica/patogenicidade
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Adhesins, Bacterial); 0 (Vitronectin); 0 (YadA protein, Yersinia); 9007-36-7 (Complement System Proteins)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171017
[Lr] Data última revisão:
171017
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161101
[St] Status:MEDLINE
[do] DOI:10.1159/000449200


  9 / 1989 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27871448
[Au] Autor:Chen MH; Lu C; Sun J; Chen XD; Dai JX; Cai JY; Chen XL
[Ad] Endereço:Department of Neurosurgery, The Central Hospital of Wenzhou City, Wenzhou Medical University Dingli Clinical College, 32 Dajian Lane, Wenzhou 325000, Zhejiang Province, China.
[Ti] Título:Diagnostic and prognostic value of serum vitronectin levels in human glioma.
[So] Source:J Neurol Sci;371:54-59, 2016 Dec 15.
[Is] ISSN:1878-5883
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: Vitronectin is an extracellular matrix protein, the synthesis of which by glioma cells correlates with tumor grade. The current study was designed to investigate the relationship between serum vitronectin levels and clinicopathological characteristics, diagnosis and prognosis in glioma patients. METHODS: In a prospective observatory study, a total of 98 glioma patients, 98 healthy controls, 98 other non-glioma brain tumors, and 98 other non-tumor neurological diseases were recruited. Following univariate analyses, multivariate analyses were performed to explore the associations of serum vitronectin levels with survival and clinicopathological parameters. Receiver operating characteristic curve analysis was done to assess its diagnostic and prognostic predictive value. RESULTS: Serum vitronectin levels were significantly elevated in glioma patients as compared with other groups. High Wealth Health Organization grade was independently associated with high vitronectin levels. Serum vitronectin levels could significantly distinguish glioma patients from other groups and discriminate high-grade glioma from low-grade glioma. Vitronectin levels markedly predicted 5-year progression and 5-year mortality. Moreover, serum vitronectin was identified as an independent predictor for 5-year overall survival and 5-year progression-free survival as well as 5-year mortality and 5-year progression. CONCLUSION: Serum vitronectin may be a promising diagnostic and prognostic biomarker that can be detected in the peripheral blood of patients with glioma.
[Mh] Termos MeSH primário: Neoplasias Encefálicas/sangue
Glioma/sangue
Vitronectina/sangue
[Mh] Termos MeSH secundário: Adulto
Fatores Etários
Idoso
Biomarcadores Tumorais/sangue
Neoplasias Encefálicas/mortalidade
Neoplasias Encefálicas/patologia
Neoplasias Encefálicas/terapia
Progressão da Doença
Feminino
Glioma/mortalidade
Glioma/patologia
Glioma/terapia
Seres Humanos
Masculino
Meia-Idade
Gradação de Tumores
Prognóstico
Estudos Prospectivos
Análise de Sobrevida
Resultado do Tratamento
Carga Tumoral
[Pt] Tipo de publicação:JOURNAL ARTICLE; OBSERVATIONAL STUDY
[Nm] Nome de substância:
0 (Biomarkers, Tumor); 0 (Vitronectin)
[Em] Mês de entrada:1705
[Cu] Atualização por classe:170817
[Lr] Data última revisão:
170817
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161123
[St] Status:MEDLINE


  10 / 1989 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
[PMID]:27802203
[Au] Autor:Yang XP; Zhou LX; Yang QJ; Liu L; Cai Y; Ma SL
[Ad] Endereço:Department of Hepatopancreatobiliary Surgery, Affiliated Hangzhou Hospital of Nanjing Medical University, Hangzhou First People's Hospital, Hangzhou, Zhejiang, China.
[Ti] Título:Diagnostic and prognostic roles of serum vitronectin in hepatitis B-related hepatocellular carcinoma.
[So] Source:Cancer Biomark;17(3):271-279, 2016 Sep 26.
[Is] ISSN:1875-8592
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Vitronectin (VN) might be involved in the progression of hepatocellular carcinoma (HCC). OBJECTIVE: This study was designed to evaluate the diagnostic and prognostic value of serum vitronectin among HCC patients. METHODS: A total of 105 patients with HCC, 91 with liver cirrhosis, 102 with chronic hepatitis, and 100 healthy subjects were recruited. Serum VN and alpha-fetoprotein (AFP) levels were measured. RESULTS: Serum VN levels were significantly higher in HCC patients than in the other groups. Based on area under receiver operating characteristic curve, serum VN had similar diagnostic value, compared with serum AFP, in distinguishing HCC from the groups, and also improved the diagnostic value of AFP alone. Serum VN levels were associated with the degree of histological differentiation, multiple foci, vascular tumor thrombosis and tumor node metastasis stage. Serum VN was an independent predictor for early recurrence and disease-free survival. Moreover, serum VN possessed similar prognostic predictive performance as compared to serum AFP and also significantly enhanced the prognostic value of AFP alone. CONCLUSIONS: Elevated serum VN levels represented high diagnostic value and had close relation to clinicopathological factors and early recurrence, suggesting that serum VN might be a useful diagnostic and prognostic marker for HCC.
[Mh] Termos MeSH primário: Biomarcadores Tumorais
Carcinoma Hepatocelular/sangue
Carcinoma Hepatocelular/etiologia
Hepatite B Crônica/complicações
Neoplasias Hepáticas/sangue
Neoplasias Hepáticas/etiologia
Vitronectina/sangue
[Mh] Termos MeSH secundário: Adulto
Idoso
Carcinoma Hepatocelular/diagnóstico
Carcinoma Hepatocelular/mortalidade
Estudos de Casos e Controles
Feminino
Seres Humanos
Cirrose Hepática/complicações
Neoplasias Hepáticas/diagnóstico
Neoplasias Hepáticas/mortalidade
Masculino
Meia-Idade
Recidiva Local de Neoplasia
Estadiamento de Neoplasias
Prognóstico
Estudos Prospectivos
Curva ROC
alfa-Fetoproteínas
[Pt] Tipo de publicação:JOURNAL ARTICLE; OBSERVATIONAL STUDY
[Nm] Nome de substância:
0 (Biomarkers, Tumor); 0 (Vitronectin); 0 (alpha-Fetoproteins)
[Em] Mês de entrada:1701
[Cu] Atualização por classe:170118
[Lr] Data última revisão:
170118
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161102
[St] Status:MEDLINE



página 1 de 199 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde